BioArctic: Gunilla Osswald awarded Uppsala University Alumnus of the year 2025
The motivation reads: As a business leader, she is visionary and inclusive. She creates a shared sense of purpose, a strong feeling of meaning, and a culture characterized by collaboration-both within the organization and in dialogue with external partners.
"Universities play a vital role in development and innovation. I am deeply honored by this award. Uppsala University has had a profound influence on who I have become as well as on the successes our company has achieved. My driving force has always been to help patients, and through my studies at the Faculty of Pharmacy, I laid the foundation for this important work," says
The information was released for public disclosure, through the agency of the contact person below, on
For further information, please contact:
E-mail: [email protected]
Phone: +46 70 410 71 80
Images of
https://www.bioarctic.com/en/media/image-bank/
Motivation
As a business leader, she is visionary and inclusive. She creates a shared sense of purpose, a strong feeling of meaning, and a culture characterized by collaboration-both within the organization and in dialogue with external partners.
About the Uppsala University Alumnus of the Year Award
Each year, Uppsala University presents the Alumnus of the Year award to someone who has made outstanding contributions in their career or has otherwise distinguished themselves through work that the university deems worthy of recognition. https://www.uu.se/en/about-uu/academic-traditions/traditions/alumnus-of-the-year
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://news.cision.com/bioarctic/i/gunilla-osswald,c3467996 |
View original content:https://www.prnewswire.com/news-releases/bioarctic-gunilla-osswald-awarded-uppsala-university-alumnus-of-the-year-2025-302550423.html
SOURCE BioArctic
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Suncadia Debuts Suncadia Social with a Three-Day Grand Opening Celebration, June 19-21
- POP Biotechnologies Secures Up to $9.7 Million in CEPI Funding
- Left Field Capital Corp. Issues Clarifying Press Release
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share